Dr Christopher Webster
School of Medicine and Population Health
SITraN Fellow


+44 114 22240
Full contact details
School of Medicine and Population Health
Sheffield Institute for Translational Neuroscience (SITraN)
385a Glossop Road
Sheffield
S10 2HQ
- Profile
-
2025 – Present: SITraN Fellow and MND Association Funded Principal Investigator, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
2022 – 2025: ARDAT funded Postdoctoral Research Associate, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
2019 – 2022: ARUK funded Postdoctoral Research Associate, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
2016 – 2019: Alzheimer’s Society funded Postdoctoral Research Associate and Co-investigator, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
2012 – 2016: PhD (Neuroscience), Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
2008 – 2011: 1st Class BSc Hons (Biochemistry and Genetics), University of Nottingham, Nottingham, UK
- Research interests
-
My research focusses on understanding disease mechanisms in several neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Hereditary Spastic Paraplagias (HSPs). Using this mechanistic understanding, and gene therapy expertise acquired in the laboratory of Professor Mimoun Azzouz, I aim to develop novel gene therapy based therapeutic approaches to these neurodegenerative diseases.
My research has had a particular focus on C9orf72-related ALS and FTD, with specific attention given to the function of the C9orf72 protein. A hexanucleotide repeat expansion in the first intron of the C9orf72 gene is the most common genetic cause of both ALS and FTD. The pathogenic mechanism behind this repeat expansion is complex, but there is evidence that both loss and toxic gain-of-function mechanisms are involved.
- Publications
-
Journal articles
- RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance, 8(2). View this article in WRRO
- Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47. EMBO Molecular Medicine, 16(11), 2882-2917. View this article in WRRO
- A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Molecular Therapy, 32(10), 3220-3259. View this article in WRRO
- Editorial: advanced (gene and cell) therapies for central nervous system applications. Frontiers in Molecular Neuroscience, 16.
- Ap4b1-knockout mouse model of hereditary spastic paraplegia type 47 displays motor dysfunction, aberrant brain morphology and ATG9A mislocalization. Brain Communications, 5(1). View this article in WRRO
- Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation. Frontiers in Cellular Neuroscience, 16. View this article in WRRO
- An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD. Acta Neuropathologica, 144(3), 437-464. View this article in WRRO
- C9ORF72-derived poly-GA DPRs undergo endocytic uptake in iAstrocytes and spread to motor neurons. Life Science Alliance, 5(9). View this article in WRRO
- SMN-deficient cells exhibit increased ribosomal DNA damage. Life Science Alliance, 5(8). View this article in WRRO
- SPG15 protein deficits are at the crossroads between lysosomal abnormalities, altered lipid metabolism and synaptic dysfunction. Human Molecular Genetics, 31(16), 2693-2710. View this article in WRRO
- The hybrid AAVP tool gets an upgrade. Proceedings of the National Academy of Sciences, 116(37), 18162-18164. View this article in WRRO
- Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain, 142(3), 586-605. View this article in WRRO
- C9orf72 plays a central role in Rab GTPase-dependent regulation of autophagy. Small GTPases, 9(5). View this article in WRRO
- Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Human Molecular Genetics, 26(23), 4668-4679. View this article in WRRO
- Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?. Frontiers in Molecular Neuroscience, 10. View this article in WRRO
- The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO Journal. View this article in WRRO
Conference proceedings papers
- View this article in WRRO
- Inosine reverses motor neuron toxicity observed in amyotrophic lateral sclerosis patient astrocytes with an adenosine deaminase deficiency. Biochimica et Biophysica Acta (BBA) - Bioenergetics, Vol. 1859(Supplement) (pp e23-e23). Budapest, Hungary, 25 August 2018 - 25 August 2018. View this article in WRRO
Preprints
- C9orf72-derived poly-GA DPRs undergo endocytic uptake in iNPC-derived astrocytes and spread to motor neurons, Cold Spring Harbor Laboratory.
- RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance, 8(2). View this article in WRRO
- Research group
-
PhD:
- Matthew Roach (2019/2023)
MSc:
- Daniel Hollard (2024/25)
- Alisha Khan (2024/25)
- Azita Soltanmohammadi (2023/24)
- Dana Dauletalina (2023/24 - Gordon Bramah Prize for Advanced Therapies and Divisional Prize for Best Research Project)
- Dagmara Szmaglinska (2022/23 - Gordon Bramah Prize for Advanced Therapies, Divisional Prize for Best Research Project and The Jody De Vos MND Research Award)
- Luke Cottrell (2022/23)
- Olivia Crossley (2021/22 - Divisional Prize for Best Research Project and The Jody De Vos MND Research Award)
- Current Projects
Development of novel gene therapy approaches for inherited forms of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), with a current focus on C9orf72-ALS/FTD.